FLT4 and diabetes mellitus: Systemic blockade of VEGFR-3 caused the reduction of macrophages infiltration in adipose tissue, lower levels of lipids accumulated in the liver and improved insulin sensitivity, thus, suggesting VEGF-C/VEGFR-3 as a promising target in treatments of insulin resistance-based diseases (obesity, diabetes and metabolic syndrome) [45].